Correction: PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA).
作者信息
Hori Yumiko, Hirose Katsutoshi, Ozeki Michio, Hata Kenji, Motooka Daisuke, Tahara Shinichiro, Matsui Takahiro, Kohara Masaharu, Higashihara Hiroki, Ono Yusuke, Tanaka Kaishu, Toyosawa Satoru, Morii Eiichi
机构信息
Department of Pathology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, 565-0871 Suita, Osaka, Japan.
Department of Central Laboratory and Surgical Pathology, National Hospital Organization, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka-shi, Osaka, 540-0006, Japan.
出版信息
Diagn Pathol. 2022 May 2;17(1):43. doi: 10.1186/s13000-022-01224-5.
Abstract
摘要
相似文献
1
Correction: PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA).更正：在纤维脂肪血管异常（FAVA）中，PIK3CA突变与mTOR通路表达相关，但与临床和病理特征无关。
Diagn Pathol. 2022 May 2;17(1):43. doi: 10.1186/s13000-022-01224-5.
2
PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).PIK3CA 突变与 mTOR 通路表达相关，但与纤维脂肪性血管异常（FAVA）的临床和病理特征无关。
Diagn Pathol. 2022 Jan 30;17(1):19. doi: 10.1186/s13000-022-01199-3.
3
Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.纤维脂肪血管异常（FAVA）：三例病例报告，重点介绍哺乳动物雷帕霉素靶蛋白（mTOR）通路。
Diagn Pathol. 2020 Jul 25;15(1):98. doi: 10.1186/s13000-020-01004-z.
4
Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic Mutation.伴有体细胞激活突变的纤维脂肪血管异常（FAVA）病例报告
Case Rep Genet. 2022 Aug 2;2022:9016497. doi: 10.1155/2022/9016497. eCollection 2022.
5
Fibro-Adipose Vascular Anomaly (FAVA): Not Another Vascular Anagram.纤维脂肪性血管异常（FAVA）：并非另一个血管变位词。
Int J Surg Pathol. 2023 Jul 17:10668969231188419. doi: 10.1177/10668969231188419.
6
Fibro-Adipose Vascular Anomaly of the Lower Extremity.下肢纤维脂肪血管异常
JACC Case Rep. 2024 Apr 17;29(8):102274. doi: 10.1016/j.jaccas.2024.102274.
7
Clinical and imaging features in fibro-adipose vascular anomaly (FAVA).纤维脂肪血管异常（FAVA）的临床和影像学特征。
Pediatr Radiol. 2020 Mar;50(3):380-387. doi: 10.1007/s00247-019-04571-6. Epub 2019 Dec 13.
8
Lower Extremity Fibro-Adipose Vascular Anomaly (FAVA): A New Case of a Newly Delineated Disorder.下肢纤维脂肪血管异常（FAVA）：一种新界定疾病的新病例。
Ann Vasc Dis. 2014;7(3):316-9. doi: 10.3400/avd.cr.14-00049. Epub 2014 Jul 30.
9
Fibro Adipose Vascular Anomaly: A Rare and Often Misdiagnosed Entity.纤维脂肪血管异常：一种罕见且常被误诊的病症。
Indian J Radiol Imaging. 2021 Nov 13;31(3):776-781. doi: 10.1055/s-0041-1736399. eCollection 2021 Jul.
10
Lower Extremity Fibro-Adipose Vascular Anomaly: A Post-surgical Rehabilitation Treatment.下肢纤维脂肪血管异常：术后康复治疗
Cureus. 2024 Jun 19;16(6):e62708. doi: 10.7759/cureus.62708. eCollection 2024 Jun.
引用本文的文献
1
Clinicopathological Characteristics, Gene Mutations, and Treatment of Fibro-adipose Vascular Anomaly: A Case Series From China and Literature Review.纤维脂肪性血管异常的临床病理特征、基因突变及治疗：来自中国的病例系列及文献综述
Ann Plast Surg. 2025 May 1;94(5):581-588. doi: 10.1097/SAP.0000000000004303. Epub 2025 Feb 24.
2
When, where and which PIK3CA mutations are pathogenic in congenital disorders.PIK3CA基因的哪些突变在先天性疾病中具有致病性，以及这些突变发生的时间和位置。
Nat Cardiovasc Res. 2022 Aug;1(8):700-714. doi: 10.1038/s44161-022-00107-8. Epub 2022 Aug 8.
本文引用的文献
1
PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).PIK3CA 突变与 mTOR 通路表达相关，但与纤维脂肪性血管异常（FAVA）的临床和病理特征无关。
Diagn Pathol. 2022 Jan 30;17(1):19. doi: 10.1186/s13000-022-01199-3.
Zotero 插件